v3.25.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended June 30,Six Months Ended June 30,
 2025202420252024
Net product revenue$14,726.0 $10,354.9 $26,327.2 $18,151.4 
Collaboration and other revenue
831.7 947.9 1,959.0 1,919.4 
Revenue$15,557.7 $11,302.8 $28,286.2 $20,070.8 
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended June 30, 2025 and 2024:
Three Months Ended June 30,
 20252024
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Cardiometabolic Health:
Mounjaro$3,301.8 $1,897.1 $5,198.9 $2,413.7 $677.2 $3,090.8 
Zepbound3,379.9 1.5 3,381.4 1,243.2 — 1,243.2 
Trulicity743.8 348.4 1,092.2 876.7 368.9 1,245.6 
Jardiance(1)
382.2 307.8 690.0 428.9 340.7 769.6 
Other cardiometabolic health555.7 424.7 980.4 753.6 411.7 1,165.4 
Total cardiometabolic health8,363.4 2,979.5 11,342.9 5,716.1 1,798.5 7,514.6 
Oncology:
Verzenio929.0 560.3 1,489.3 861.4 470.5 1,331.9 
Other oncology490.3 434.0 924.3 413.8 413.0 826.8 
Total oncology1,419.3 994.3 2,413.6 1,275.2 883.5 2,158.7 
Immunology:
Taltz548.8 298.8 847.6 539.4 285.3 824.7 
Other immunology152.1 255.8 408.0 60.4 197.3 257.7 
Total immunology700.9 554.6 1,255.6 599.8 482.6 1,082.4 
Neuroscience247.9 96.1 344.0 191.9 147.6 339.5 
Other82.7 118.9 201.5 52.2 155.4 207.6 
Revenue$10,814.2 $4,743.4 $15,557.7 $7,835.2 $3,467.5 $11,302.8 
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the six months ended June 30, 2025 and 2024:
Six Months Ended June 30,
 20252024
U.S.Outside U.S.TotalU.S.Outside U.S.Total
Cardiometabolic Health:
Mounjaro$5,957.7 $3,083.0 $9,040.7 $3,934.0 $963.4 $4,897.4 
Zepbound5,685.4 7.9 5,693.3 1,760.6 — 1,760.6 
Trulicity1,514.4 673.1 2,187.4 1,958.6 743.3 2,701.9 
Jardiance(1)
692.0 1,012.4 1,704.3 797.1 659.0 1,456.1 
Other cardiometabolic health1,090.6 834.5 1,925.3 1,355.8 835.9 2,191.6 
Total cardiometabolic health14,940.1 5,610.9 20,551.0 9,806.1 3,201.6 13,007.6 
Oncology:
Verzenio1,586.6 1,061.5 2,648.2 1,499.6 882.6 2,382.2 
Other oncology878.5 834.5 1,712.9 773.9 812.5 1,586.5 
Total oncology2,465.1 1,896.0 4,361.1 2,273.5 1,695.1 3,968.7 
Immunology:
Taltz1,025.3 584.2 1,609.5 886.4 542.3 1,428.8 
Other immunology253.7 480.4 734.1 110.5 377.1 487.5 
Total immunology1,279.0 1,064.6 2,343.6 996.9 919.4 1,916.3 
Neuroscience437.2 178.9 616.1 355.1 373.5 728.6 
Other182.2 232.2 414.4 98.0 351.6 449.6 
Revenue$19,303.7 $8,982.5 $28,286.2 $13,529.6 $6,541.2 $20,070.8 
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

The following table summarizes revenue by geographical area:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenue(1):
U.S.$10,814.2 $7,835.2 $19,303.7 $13,529.6 
Europe2,574.4 1,403.7 4,963.1 2,844.4 
Japan521.0 462.7 923.2 826.6 
China465.9 395.1 916.7 771.3 
Rest of world1,182.1 1,206.1 2,179.5 2,098.9 
Revenue$15,557.7 $11,302.8 $28,286.2 $20,070.8 
(1) Revenue is attributed to the countries based on the location of the customer or other party.